Transplant Diagnostics Market: By Technology (Molecular Assay Technologies (PCR-Based Molecular Assays (Real-time PCR, Sequence-specific Primer-PCR, Sequence-specific Oligonucleotide-PCR, Other PCR-based Molecular Assays), Sequencing-based Molecular Assays (Sanger Sequencing, Next Generation Sequencing, Other Sequencing-based Molecular Assays), Non-molecular Assay Technologies), By Product & Service (Reagents & Consumables, Instruments, Software & Services), By Transplant Type (Solid Organ Transplantation (Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Pancreas Transplantation, Other Organ Transplantations), Stem Cell Transplantation, Soft Tissue Transplantation, Bone marrow Transplantation) By Application (Diagnostic Applications (Pre-transplantation Diagnostics, (Infectious Disease Testing, Histocompatibility Testing, Blood Profiling), Post-transplantation Diagnostics), Research Applications), By End User (Independent Reference Laboratories, Hospitals & Transplant Centers, Research Laboratories & Academic Institutes) and Geography  

Transplant Diagnostics Market size was valued at USD 4.1 billion in 2022  and is poised to grow at a CAGR of 7.8% from 2022 to 2029. One of the main factors driving the expansion of the market under study is the increase in organ donation. In January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the year before, according to figures released by the Association of Organ Procurement Organizations (AOPO). Over 36,500 organs were donated from deceased donors in 2020, an increase of nearly 2% compared to the previous year. For the seventh consecutive year, these recovered organs saved more lives more than 33,000 than they did the year before. Donation after Circulatory Death (DCD) contributions also saw significant increases; they totalled more than 3,000 donors, an 18% rise from the previous year. Increased transplant diagnostic testing will result from increased organ donation, propelling market expansion. The diagnosis of pulmonary function and general health is emphasized much in the context of heart transplants. The diagnostics have considerably improved over the last ten years due to businesses dedicated themselves to creating better HLA typing technologies, antibody monitoring, equipment, and software. This is rapidly employed for diagnostic purposes during organ transplantation across various body parts. Multispecialty hospitals in developed markets are doing many more transplant procedures due to technical developments and expanding financial opportunities made possible by public-private partnerships. To assess the level of infection inside an organ, the diagnosis for transplantation is carried out at the donor and patient's ends. Additionally, several significant players are releasing new products on the market, which is anticipated to further fuel market expansion. For instance, in September 2021, Thermo Fisher Scientific added two new products to its range of transplant diagnostics during the American Society for Histocompatibility and Immunogenetics (ASHI) annual meeting.